Daily Application of an Aqueous, Acidifying, Peelable Nail Polish versus Weekly Amorolfine for Topical Onychomycosis Treatment: A Prospective, Randomized, Blinded Trial

Frank Eertmans, Nejib Doss, Bart Rossel, Els Adriaens, Frank Eertmans, Nejib Doss, Bart Rossel, Els Adriaens

Abstract

Introduction: Onychomycosis is a fungal nail infection, frequently caused by dermatophytes, which occurs in 2-14% of Western adults. The present study was set up to evaluate the efficacy and safety of a water-based, peelable nail polish (daily application), which acidifies the nail environment, versus a 5% amorolfine nail lacquer (weekly application) for topical treatment of mild-to-moderate onychomycosis.

Methods: One hundred two adults were randomized in this open, prospective, blinded trial. Clinical efficacy was evaluated at baseline and days 30, 60, 120, and 180, respectively. All patients underwent microbiological testing (at baseline and study end). The primary objective of this trial was the change in the percentage of healthy nail surface at day 180.

Results: The percentage of healthy surface between baseline and day 180 increased with 11.8% in the test product group and 13.2% in the amorolfine group, which were statistically comparable. Other onychomycosis-related parameters (dystrophy, discolouration, thickening, and healthy aspect, respectively) showed significant (p < 0.05) improvement after 180 days (versus baseline) with both treatments. Clinical performance was further confirmed by the frequency of patients showing onychomycosis improvement or success at the end of the study: 96.0% (test product) versus 79.6% (amorolfine). Microbiological results and improved quality of life confirmed clinical performance. Both treatments were well tolerated and appreciated for their properties and efficacy.

Conclusion: The present trial confirmed the clinical performance of daily acidification of the nail, as reflected by (1) a comparable increase of percentage of healthy nail surface following treatment with the test product versus amorolfine, (2) the overall improvement of other onychomycosis-related parameters, (3) user convenience, and (4) absence of side effects. These data indicate that daily application of an aqueous, acetic acid-based, peelable solution can be a convenient, safe, and equally effective alternative for the topical management of onychomycosis.

Trial registration: ClinicalTrials.gov identifier; NCT03382717 FUNDING: Oystershell Laboratories.

Keywords: Amorolfine nail lacquer; Nail acidification; Onychomycosis; Water-based peelable polish.

Figures

Fig. 1
Fig. 1
CONSORT Flow chart (ITT population)
Fig. 2
Fig. 2
Onychomycosis improvement in function of time following treatment with test product and reference, respectively

References

    1. Chabasse D, Pihet M. Mycological diagnosis of onychomycosis. J Mycol Med. 2014;24:269–278. doi: 10.1016/j.mycmed.2014.10.006.
    1. Piraccini BM, Alessandrini A. Onychomycosis: a review. J Fungi. 2015;1:30–43. doi: 10.3390/jof1010030.
    1. Elewski BE. Onychomycosis: pathogenesis, diagnosis and management. Clin Microbiol Rev. 1998;11:415–429.
    1. Ghannoum M, Isham N. Fungal nail infections (Onychomycosis): a never-ending story? PLoS Pathog. 2014;10:e1004105. doi: 10.1371/journal.ppat.1004105.
    1. Baran R, Hay RJ. New clinical classification for onychomycoses. J Mycol Med. 2014;24:247–260. doi: 10.1016/j.mycmed.2014.10.004.
    1. Shirwaikar AA, Thomas T, Shirwaikar A, Lobo R, Prabhu KS. Treatment of onychomycosis: an update. Ind J Pharm Sci. 2008;70:710–714. doi: 10.4103/0250-474X.49088.
    1. Bunyaratavej S, Leeyaphan C, Chayangsu O, Bunyaratavej S, Kulthanan K. Onychomycosis: a study or self-recognition by patients and quality of life. Indian J Dermatol Venerol Leprol. 2015;81:270–274. doi: 10.4103/0378-6323.154796.
    1. Elewski BE, Tosti A. Risk factors and comorbidities for onychomycosis. J Clin Aesthet Dermatol. 2015;8:38–42.
    1. Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol. 2014;7:10–18.
    1. Sleven R, Lanckacker E, Delputte P, Maes L, Cos P. Evaluation of topical antifungal products in an in vitro onychomycosis model. Mycoses. 2016;59:327–330. doi: 10.1111/myc.12475.
    1. Kunert J. Physiology of keratinophilic fungi. In: Biology of dermatophytes and other keratinophilic fungi. In: Kushwaha, RKS, Guarro (eds.) Revista Iberoamericana de Micología, Bilbao. 2000;77–85.
    1. Polak A. Preclinical data and mode of action of amorolfine. Dermatology. 1992;184:3–7. doi: 10.1159/000247588.
    1. Lim CS, Lim SL. Practical tip: Chicago Sky Blue (CSB) stain can be added to the routine potassium hydroxide (KOH) wet-mount to provide a color contrast and facilitate the diagnosis of dermatomycoses. Dermatol Online J. 2011;17:11.
    1. Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists’ offices in Ontario, Canada—a multicenter survey of 2001 patients. Int J Dermatol. 1997;36:783–787. doi: 10.1046/j.1365-4362.1997.00349.x.
    1. Kaliyadan F, Manoj J, Venkitakrishnan S, Dharmaratnam AD. Basic digital photography in dermatology. Indian J Dermatol Venerol Leprol. 2008;74:532–536. doi: 10.4103/0378-6323.44334.
    1. Warshaw EM, Foster JK, Cham PM, Grill JP, Chen SC. NailQoL: a quality-of-life instrument for onychomycosis. Int J Dermatol. 2007;46:1279–1286. doi: 10.1111/j.1365-4632.2007.03362.x.
    1. Evans EGV. The rationale for combination therapy. Br J Dermatol. 2001;145(suppl 60):9–13. doi: 10.1046/j.1365-2133.2001.145s60009.x.
    1. Roseeuw D. Achilles foot screening project: preliminary results of patients screened by dermatologists. J Eur Acad Dermatol Venereol. 1999;12:S6–S9. doi: 10.1111/j.1468-3083.1999.tb00909.x.
    1. Del Palacio A, Cuetara MS, Garau M, Perea S. Onychomycosis: a prospective survey of prevalence and etiology in Madrid. Int J Dermatol. 2006;45:874–876. doi: 10.1111/j.1365-4632.2006.01397.x.
    1. Svejgaard EL, Nilsson J. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses. 2004;47:131–135. doi: 10.1111/j.1439-0507.2004.00968.x.
    1. Trepanier EF, Amsden GW. Current issues in onychomycosis. Ann Pharmacother. 1998;32:204–214. doi: 10.1345/aph.17006.
    1. Iorizzo M, Harmane I, Derveniece A, Mikazans I. Ciclopirox 8% HPCH nail lacquer in the treatment of Mild-to-moderate onychomycosis: a randomized, double-blind amorolfine controlled study using a blinded evaluator. Skin Appendage Disord. 2016;1:134–140. doi: 10.1159/000441569.
    1. Auvinen T, Tiihonen R, Soini M, Wangel M, Sipponen A, Jokinen JJ. Efficacy of a topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis: a prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial. Br J Dermatol. 2015;173:940–948. doi: 10.1111/bjd.13934.
    1. Guo J, Brosnan B, Furey A, Arendt E, Murphy P, Coffey A. Antifungal activity of Lactobacillus against Microsporum canis, Microsporum gypseum and Epidermophyton floccosum. Bioeng Bugs. 2012;3:102–111.
    1. Lastauskiene E, Zinkeviciene A, Girkontaite I, Kaunietis A, Kvedariene V. Formic acid and acetic acid induce a programmed cell death in pathogenic Candida species. Curr Microbiol. 2014;69:303–310. doi: 10.1007/s00284-014-0585-9.
    1. Lind H, Jonsson H, Schnurer J. Antifungal effect of dairy propionibacteria— contribution of organic acids. Int J Food Microbiol. 2005;98:157–165. doi: 10.1016/j.ijfoodmicro.2004.05.020.
    1. Adimi P, Hashemi SJ, Mahmoudi M, Mirhendi H, Shidfar MR, Emmami M, et al. In-vitro activity of 10 antifungal agents against 320 dermatophyte strains using microdilution method in tehran. IJPR. 2013;12:537–545.
    1. Smith KA, Hao J, Kevin L. Effects of organic solvents on the barrier properties of human nail. J Pharm Sci. 2011;100:4244–4257. doi: 10.1002/jps.22590.
    1. Ghannoum M, Sevin K, Sarkany M. Amorolfine 5% nail lacquer exhibits potent antifungal activity compared to three acid-based devices indicated for the treatment of onychomycosis: an in vitro nail penetration assay. Dermatol Ther (Heidelb) 2016;6:451. doi: 10.1007/s13555-016-0124-7.
    1. Eertmans F, Doss N, Rossel B, Regidor PA. Nail acidification versus amorolfine in the local management of onychomycosis. A comparative, prospective, randomized, blinded trial. Int Educ Appl Sci Res. 2017;2:3–6.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren